The emerging class of amyloid-targeting therapies (ATTs) are at the forefront of innovative approaches that promise to alter the course of Alzheimer’s disease (AD). However, the translation of these scientific advancements into clinical practice necessitates a well-informed clinical workforce adept in the latest science, diagnostic tools, and therapeutic protocols pertaining to the amyloid and tau pathology of AD and ATTs. It is crucial that clinicians receive targeted, relevant, and applicable education to achieve accurate diagnoses and appropriate treatment selection for patients with early symptomatic AD.
In this second installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will evaluate the latest data from ATT clinical trials and discuss strategies for identifying appropriate patients based on both pathological and clinical characteristics to ensure timely and optimal management of patients with early symptomatic AD.
